STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa
NCT00006053
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
INDUSTRY
Sponsor class
Conditions
Leukemia
Interventions
DRUG:
imatinib mesylate
Sponsor
Novartis